Results 161 to 170 of about 6,896,729 (296)

Alternative models of consent in out-of-hospital transfusion trials: a CAN-PATT position statement supporting exception from prospective consent with opt-out notification. [PDF]

Scand J Trauma Resusc Emerg Med
Peddle M, Greene A, Trojanowski J, Shih AW, Chang E, Nahirniak S, Pearson D, Prokopchuk-Gauk O, Martin D, Musuka C, Seidl C, Lin Y, MacDonald S, Richards L, Farrell M, Miller D, McGowan M, Nolan B.   +17 more
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Opt In v. Opt Out v. Mixed Systems: a Defense of Opt Out as a Model for Collective Actions

, 2015
Research focuses on the study of opt in, opt out and other mixed systems as models to collective redress around the world, especially in America and in Europe, analyzing how do they work in class actions and in mechanism for solving collective suits ...
Pochmann Da Silva, Larissa
core  

Q&A: Re-review opt-out and painless publishing

BMC Biology, 2013
Robertson Miranda
doaj   +1 more source

Parent and practitioner experiences of opt-out consent in neonatal intensive care: a mixed methods study within a trial. [PDF]

Arch Dis Child Fetal Neonatal Ed
Mitchell T, Andrzejewska I, Battersby C, Cole C, Daskalopoulou Z, Dorling J, Gale C, Graham M, Hubbard M, Hardy P, Hurd M, King AR, Manley BJ, Murray D, Nuthall E, O'Connor H, Ojha S, Roberts CT, Rodriquez A, Roehr CC, Stanbury K, Tume L, Young L, Woolfall K.   +23 more
europepmc   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

Does opt-out system increase the rate of organ donation?

, 2018
Cílem práce je komparovat přístupy opt-in a opt-out a jejich vliv na míru dárcovství orgánů. Přístup opt-in je definován jako systém dárcovství, ve kterém jedinec není automaticky považován za dárce orgánů v případě smrti.
Hovorková, Adina
core  

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Opt-Out Screening for Blood-Borne Viruses in Trauma and Orthopaedic Admissions From the Emergency Department: Are We Meeting the Standards? [PDF]

Cureus
Shahbaz A, Walker M, Imami F, Mahajan U, Shahbaz R, Bose D.   +5 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source